NCT00798252 2015-07-07
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers
Bristol-Myers Squibb
Phase 1 Completed
Clinical Trials
10 trialsNCT01046864 2014-09-16
Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)
Bristol-Myers Squibb
Phase 1 Completed
NCT01540461 2014-07-08
Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)
Bristol-Myers Squibb
Phase 1 Completed
NCT00437437 2013-06-21
A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)
Bristol-Myers Squibb
Phase 1 Completed
NCT00437424 2011-05-04
A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction
Bristol-Myers Squibb
Phase 1 Completed
NCT00207051 2011-01-25
BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies
Bristol-Myers Squibb
Phase 1 Completed
NCT00390936 2011-01-25
A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT00300027 2010-03-02
Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies
Bristol-Myers Squibb
Phase 1 Terminated
NCT00435669 2009-01-22
A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)
Bristol-Myers Squibb
Phase 1 Completed
NCT00207103 2008-11-04
MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed